PADAGIS ANNOUNCES THE LAUNCH OF BRINZOLAMIDE OPHTHALMIC SUSPENSION WITH CGT EXCLUSIVITY
13 Oct 2023
ALLEGAN, Mich., Oct. 13, 2023 /PRNewswire/ -- Padagis today announced the launch of Brinzolamide Ophthalmic Suspension with Competitive Generic Therapy (CGT) exclusivity (generic equivalent to the Reference Listed Drug Azopt® Ophthalmic Suspension).
Azopt® Ophthalmic Suspension is indicated to decrease elevated intraocular pressure (IOP) in adult patients with ocular hypertension or open-angle glaucoma, as monotherapy in patients unresponsive to betablockers or in patients in whom beta-blockers are contraindicated, or as adjunctive therapy to betablockers. Annual market sales for Azopt® were approximately $74 million in the 12 months ended August 2023 as measured by IQVIA.
Padagis President, Pamela Hoffman, stated, "This launch and its accompanying CGT exclusivity demonstrates the ability of the Padagis team to bring complex generic products to the markets that need them. The Padagis team continues to leverage our unique and specialized technical and commercial capabilities to deliver important products to our customers and patients."
About Padagis
Padagis is dedicated to improving the well-being of patients and consumers by providing high quality, affordable, specialized healthcare products. The company is a leading provider of extended topical and other specialty pharmaceuticals to its primary markets of the United States and Israel. Padagis employs over 1,300 people worldwide. Visit Padagis online at (http://www.padagis.com).
SOURCE Padagis
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.